No published or registered trial has tested a CJC-1295 plus ipamorelin dose in humans. Every number on a vendor dosing chart is copied between sellers, not derived from a study.
The honest answer to CJC-1295 and ipamorelin dosing is that no dose comes from a trial of the two together. The stack has never been tested in a published human study, so every number on a vendor chart is an inference from the individual peptides. What can be stated from evidence is how each one behaves. CJC-1295 with DAC lasts for days, ipamorelin clears in a matter of minutes, and the two are dosed on completely different schedules because of it.
- No published or registered trial has tested a CJC-1295 plus ipamorelin dose in humans, so any specific protocol is physician-determined and off-label
- CJC-1295 with DAC has an estimated half-life of 5.8 to 8.1 days, which is why it is dosed weekly rather than nightly [1]
- Ipamorelin is short-acting and dosed for a single pulse, usually at bedtime alongside the GHRH analog [3]
- The two peptides run on different clocks, and that duration mismatch is the part most stacking charts skip [1][3]
- A baseline IGF-1 before the first injection and a retest at about 90 days are what make any dose measurable [1]
- FDA has identified serious adverse events for CJC-1295 and flags ipamorelin as a compounding safety risk; both are prohibited in sport at all times [4][5][6]
Why There Is No Trial-Established Dose for This Stack
Start with what is missing. There is no published trial of CJC-1295 combined with ipamorelin, at any dose, in any population. The two-pathway rationale behind the pairing is real and shown in humans, but with different molecules. A GHRH analog plus a secretagogue produced a GH response well above the sum of each alone [2].
That study used GHRP-6, not ipamorelin, so it supports the direction of the effect rather than a dose ratio for this stack. This is why a dosing chart printed on a sales page carries no evidentiary weight. The numbers are copied between vendors, not derived from a study. A dose worth following comes from a prescribing physician working from your labs, set off-label because neither peptide has an approved product to label.
How CJC-1295 Dosing Frequency Works
CJC-1295 dosing frequency follows its half-life, and the half-life depends entirely on which version is in the vial. CJC-1295 with DAC carries an albumin-binding group that gives it an estimated half-life of 5.8 to 8.1 days [1]. A single dose raised plasma GH 2 to 10-fold for 6 or more days and IGF-1 for 9 to 11 days, and repeated dosing kept IGF-1 above baseline for up to 28 days [1]. A peptide that acts for that long is dosed weekly or twice weekly, not nightly.
CJC-1295 without DAC is a different drug. It lacks the albumin tether, clears in hours, and behaves closer to sermorelin in duration. It has no controlled human trials behind it. If a program does not state which form it dispenses, that is the first question to ask, because the injection schedule depends on the answer.
How Ipamorelin Is Dosed Alongside It
Ipamorelin is dosed on the opposite clock. It is a selective secretagogue that acts on the ghrelin receptor and is short-acting, so it contributes a single sharp GH pulse rather than sustained elevation [3]. That short action is why it is timed to bedtime, aligning the pulse with the body's natural nocturnal GH release rather than a background elevation that never falls.
Because it clears fast, ipamorelin is the peptide dosed most frequently in the stack, usually once at night and in some protocols split into more than one pulse, on an empty stomach. It is almost never run alone. Its value in the stack is the second pathway it adds, and its only published human efficacy trial, for postoperative ileus, missed its endpoint [7].
The Duration Mismatch Is the Real Schedule Question
Here is the design problem the charts skip. CJC-1295 with DAC sustains GH and IGF-1 for days [1], while ipamorelin produces a pulse and is gone in minutes [3]. Layering a short nightly pulse on top of a multi-day elevation is a different physiologic pattern from the nightly-pulse rhythm GH-axis therapy is built to mimic.
Whether that sustained-plus-spike pattern is better or worse than a well-timed nightly pulse has not been tested. It is a fair question to put to a prescriber. Some clinicians prefer CJC-1295 without DAC for exactly this reason, since its shorter action keeps both halves of the stack on a similar clock.
| CJC-1295 with DAC | Ipamorelin | |
|---|---|---|
| Half-life | 5.8 to 8.1 days [1] | Minutes [3] |
| Dosing frequency | Weekly or twice weekly [1] | Nightly, sometimes split |
| Timing rationale | Sustained background elevation [1] | Short pulse aligned to bedtime [3] |
| Run alone? | Sometimes | Almost never [3] |
Titration Is Guided by IGF-1, Not a Chart
Titration is done against IGF-1, not a fixed schedule. The starting point for any GH-axis protocol is a baseline IGF-1 drawn before the first injection. Without that number there is no way to tell whether a dose is doing anything or pushing IGF-1 above the age-adjusted range.
IGF-1 is retested at about 90 days, the point at which the response is expected to plateau [1]. A result above the age-adjusted reference range is a reason to reduce the dose, not to hold it. The canonical anchor for comparison is sermorelin, dosed at 100 to 300 mcg per day subcutaneously at bedtime and adjusted the same way, by retest rather than by feel.
The Safety Ceiling and the Red Flags
The ceiling on any of these protocols is set by IGF-1 and by symptoms, not by how much the vial holds. Water retention, joint stiffness, and carpal-tunnel-type tingling are the familiar signs of pushing GH activity too high, and they resolve when the dose comes down. They are a signal to retest, not to continue.
The regulatory signals belong in any dosing decision. FDA states it has identified serious adverse events for CJC-1295, including increased heart rate and systemic vasodilatory reaction [4]. It lists ipamorelin acetate among bulk substances flagged as a compounding safety risk, and an FDA advisory committee voted 0 in favor and 12 against permitting it for compounding in October 2024 [5]. Both are named on the 2026 WADA Prohibited List, prohibited at all times [6].
A program that sets a CJC-1295 and ipamorelin dose without drawing a baseline IGF-1 first has skipped the one step that makes the dose measurable. A fixed dose handed out at checkout, identical for every patient, is a marketing number, not a clinical one.
The Honest Verdict
There is no trial-established dose for CJC-1295 and ipamorelin, and anyone who states otherwise is reading a vendor chart. What the evidence does support is the structure. CJC-1295 with DAC on a weekly clock, ipamorelin as a short nightly pulse, both titrated against IGF-1 rather than a fixed number.
If you pursue the stack, the discipline is the same as for any GH-axis protocol. Draw a baseline IGF-1 first. Confirm which form of CJC-1295 a licensed prescriber is dispensing. Retest at 90 days and treat a result above the age-adjusted range as a reason to lower the dose. The dose that matters is the one built from your labs.
CJC-1295 and ipamorelin have no trial-established dose, so a starting IGF-1 and a 90-day retest are what turn a protocol into something measurable. SystemLabs tests IGF-1 before prescribing and formulates CJC-1295 and ipamorelin on clinical indication, so the dose is built from your labs rather than a fixed chart.
Frequently Asked Questions
What is the correct dose of CJC-1295 and ipamorelin?
There is no trial-established dose, because no published human study has tested the two together [2]. Any specific protocol is physician-determined and off-label, since neither peptide has an FDA-approved product to label. A dose worth following is set by a prescriber working from a baseline IGF-1, not from a vendor chart.
How often do you inject CJC-1295 and ipamorelin?
On different schedules, because the two act on different clocks. CJC-1295 with DAC has a half-life of 5.8 to 8.1 days and is dosed weekly or twice weekly [1], while ipamorelin is short-acting and dosed daily, usually once at bedtime and sometimes split [3]. The exact frequency for CJC-1295 depends on whether the DAC or no-DAC form is dispensed.
When should you take CJC-1295 and ipamorelin?
Ipamorelin is timed to bedtime on an empty stomach, so its short pulse aligns with the body's natural nocturnal GH release [3]. CJC-1295 with DAC lasts for days, so its timing is less about the clock and more about a consistent weekly schedule [1]. Food within about two hours blunts the GH response, which is why both are dosed fasting at night.
Do you need a prescription and labs for CJC-1295 and ipamorelin?
Yes. Both are dispensed only as compounded preparations and require a prescribing physician, and a responsible protocol starts from a baseline IGF-1 drawn before the first injection [1]. A program that sets a dose without that baseline has skipped the one step that makes the dose measurable.
Is there a maximum safe dose of CJC-1295 and ipamorelin?
The ceiling is set by IGF-1 and by symptoms, not by a fixed milligram number. An IGF-1 above the age-adjusted range at the 90-day retest is a reason to lower the dose [1], and water retention, joint stiffness, or carpal-tunnel-type tingling are signs of too much GH activity that resolve when the dose comes down. FDA has also identified serious adverse events for CJC-1295, including increased heart rate and systemic vasodilatory reaction [4].
How do you titrate CJC-1295 and ipamorelin?
Against IGF-1, not against how you feel. A baseline IGF-1 is drawn first, and the peptide is retested at about 90 days, the point where the response is expected to plateau [1]. A result inside the age-adjusted range with symptom improvement supports holding the dose; a result above the range is a reason to reduce it.
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6 Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 8045963. https://pubmed.ncbi.nlm.nih.gov/8045963/
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024 FDA Advisory Committee, 2024. PCAC summary minutes. https://www.fda.gov/media/185412/download
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, 2014. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
